Precision Ocular Network – Flowood in Flowood underwent a Food and Drug Administration (FDA) inspection on Feb. 6 related to human cellular, tissue, and gene therapies, according to data published on the FDA’s website.
The closing report stated that Precision Ocular Network – Flowood was not required to take corrective measures regarding the organization’s management and operations.
The FDA conducts regular inspections of facilities throughout the United States to assess whether workplaces and their products adhere to FDA regulations, which are enforced to safeguard public health. The results of these inspections are made publicly available.
Its website states that the FDA is the federal agency chiefly charged with overseeing the manufacturing and supply of drugs for humans and animals, as well as biological products, medical devices and tobacco products, to ensure their safety and quality.
Information for this article comes from the U.S. Food and Drug Administration. Source data is available here.
